Imugene Ltd's (ASX:IMU) (OTCMKTS:IUGNF) Leslie Chong speaks to Proactive's Andrew Scott following the news they've entered a licensing agreement with City of Hope®, a world-renowned independent cancer research and treatment centre near Los Angeles, for the patents covering a novel combination immunotherapy. The therapy unleashes a CD19 expressing oncolytic virus to enable CD19 directed chimeric antigen receptor (CAR) T cell therapies to target solid tumours, which are currently otherwise difficult to treat with CAR T cell therapy alone.
Imugene Ltd's Leslie Chong delighted to bring onCARlytics therapy home 'where it belongs'
